Loading clinical trials...
Loading clinical trials...
A Phase I Open-label Study of EDP1503 Alone and in Combination With Pembrolizumab in Patients With Advanced Metastatic Colorectal Carcinoma, Triple-negative Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors
Conditions
Interventions
EDP1503
Pembrolizumab
Locations
8
United States
Highlands Oncology Group
Rogers, Arkansas, United States
Florida Cancer Specialists
Sarasota, Florida, United States
Stephenson Cancer Center
Oklahoma City, Oklahoma, United States
Tennessee Oncology, PLLC
Chattanooga, Tennessee, United States
Tennessee Oncology
Nashville, Tennessee, United States
Centre de Recherche du CHUM
Montreal, Quebec, Canada
Start Date
December 19, 2018
Primary Completion Date
June 30, 2021
Completion Date
October 31, 2021
Last Updated
March 24, 2023
NCT05671510
NCT03340506
NCT06681064
NCT05005403
NCT06547840
NCT06634875
Lead Sponsor
Evelo Biosciences, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions